 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| «12345678910111213...1314» |
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P4 trial, Metastases: FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) - Apr 20, 2021
P4, N=33, Recruiting, Sponsor: University of Ljubljana, Faculty of Medicine
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
@novonordisk Which is better for a chronic diabetic in simple terms please? #FIASP or #Novorapid. (Twitter) - Apr 3, 2021
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - Mar 24, 2021
P4, N=260, Recruiting, Sponsor: Emory University
Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Aug 2022 --> Sep 2024
- || NovoLog (insulin aspart) / Novo Nordisk
Pricing: That was for 1 vial of Novolog (NovoRapid). If you buy three, it was under $60 per vial, so basically 20% of the cost in the US. (Twitter) - Mar 9, 2021
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Can you configure the type of insulin (e.g. FIASP) or is it fixed to NovoRapid? (Twitter) - Mar 6, 2021
- || Tresiba (insulin degludec) / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date, Surgery: Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes (clinicaltrials.gov) - Mar 4, 2021
P4, N=182, Active, not recruiting, Sponsor: Emory University
Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Aug 2022 --> Sep 2024 Suspended --> Active, not recruiting | Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021
- | NovoLog (insulin aspart) / Novo Nordisk
@novonordiskus opened a brand new Novolog pen yesterday, and today the insulin is dead. What now? (Twitter) - Feb 25, 2021
- | NovoLog (insulin aspart) / Novo Nordisk
Novolog is used more often by type 1s (Twitter) - Feb 16, 2021
- || NovoLog (insulin aspart) / Novo Nordisk
Novolog doing well for you guys? (Twitter) - Feb 3, 2021
- Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Case Series: Exacerbation of Insulin Resistance With Active COVID 19 Infection (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_1102;
Cconsideration should be given to assessing therapeutic interventions to enhance insulin sensitivity and improve outcomes. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Phase classification: Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal (clinicaltrials.gov) - Jan 27, 2021
P4, N=72, Recruiting, Sponsor: Medical University of Warsaw
Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20. Phase classification: P3 --> P4
- | Admelog (insulin lispro biosimilar) / Sanofi, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
Journal: Lyumjev - a new insulin lispro for diabetes. (Pubmed Central) - Jan 26, 2021
Phase classification: P3 --> P4 No abstract available
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Jan 26, 2021
P4, N=100, Recruiting, Sponsor: The Cleveland Clinic
No abstract available Not yet recruiting --> Recruiting
- || SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
Clinical, Journal, Combination therapy: Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: A randomized, open-label trial (GEMELLI 1). (Pubmed Central) - Jan 23, 2021
P3
Not yet recruiting --> Recruiting SAR-Asp demonstrated effective glycemic control with a similar safety and immunogenicity profile to NN-Asp in people with diabetes treated for 26 weeks.
- ||| NovoLog (insulin aspart) / Novo Nordisk
Given how close Humalog & Novolog prices are I would bet good money that Eli Lilly (@LillyPad) & @novonordisk are price fixing in a monopolistic cartel. Absolute Swine. (Twitter) - Jan 15, 2021
- || SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin. (Pubmed Central) - Jan 13, 2021
P3
SAR-Asp demonstrated effective glycemic control with a similar safety and immunogenicity profile to NN-Asp in people with diabetes treated for 26 weeks. Efficacy and safety (including immunogenicity) profiles of SAR-Asp are similar to those of NN-Asp over 52 weeks in adults with diabetes irrespective of prior type of mealtime insulin.
- || BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Understanding Patients' Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market. (Pubmed Central) - Jan 8, 2021
P=N/A
In India, patients with T2DM previously treated with BHI were willing to pay for BIAsp 30 in an insulin pen. Furthermore, treatment and device satisfaction improved after this therapeutic switch.
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: The impact of «faster aspart» on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump (Pubmed Central) - Jan 3, 2021
Furthermore, treatment and device satisfaction improved after this therapeutic switch. Faster aspart achieves better glycaemic control by increasing glucose time in range in children and adolescents with T1DM on treatment with sensor-augmented pumps.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Dec 27, 2020
P4, N=100, Not yet recruiting, Sponsor: The Cleveland Clinic
Faster aspart achieves better glycaemic control by increasing glucose time in range in children and adolescents with T1DM on treatment with sensor-augmented pumps. Trial completion date: Oct 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Dec 2021
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Dec 27, 2020
P3, N=160, Recruiting, Sponsor: Boston Medical Center
Trial completion date: Oct 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | NovoLog (insulin aspart) / Novo Nordisk
@novonordisk novofine 4mm needles can not be found worldwide ... is there a reason ? (Twitter) - Dec 27, 2020
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] A Quality Improvement Project at a Community Based Hospital Utilizing a Basal-Bolus Protocol for Optimization of Blood Glucose Control () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4327;
If the collaborative practice agreement is approved, it will then be presented to the Local Medical Executive Committee to be approved for pharmacy dosing. Following initiation of the basal-bolus protocol, data will be collected and compared to pre-implementation data to evaluate effectiveness.
- Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Proper diagnosis of latent autoimmune diabetes in adults prompts appropriate pharmacotherapy; C-peptide is just the beginning () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3504;
This glucose increase actually occurs due to the decline of efficacy from oral medications, because they do not address the lack of insulin production and need for supplementation. Recognition of the signs of LADA and proper diagnostic testing can lead to earlier optimal treatment with insulin and prevention of diabetes complications.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Medication Use Evaluation of Rapid acting insulin at large teaching institution and cost analysis () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3411;
Aspart is available as 10 mL vial and Lispro is available as 3 mL vial. Analysis revealed that patients received unnecessary additional vials due to our current practice and that the initial vials were not fully utilized.
- Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
[VIRTUAL] Evaluation of glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease (NAFLD) in non-diabetic and diabetic patients () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1358;
Superiority was not established for GLP-1RA compared to insulin, sitagliptin, metformin, or diet/exercise. Insufficient evidence exists to establish the effectiveness of GLP-1RA in a non-diabetic population.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Evaluating the effects of a pharmacist-driven insulin protocol on glycemic control in critically ill patients () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1322;
Expanding pharmacist-driven insulin protocols to other units and hospitals would likely further improve dysglycemia in other critically ill patients. Larger, randomized studies including additional centers are needed to validate these findings.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Cost/waste analysis of insulin dispenses in a community hospital setting () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1252;
A new process has been developed to dispense individual insulin doses from a secure bin in the automated dispensing cabinet. This new practice will decrease the amount of insulin waste, thus lowering the costs currently associated with the insulin management process.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Health outcomes and economic impacts in veterans converted from insulin aspart vials to pens () - Dec 26, 2020 - Abstract #ASHP2020ASHP_896;
Differences in average HbA1C, total cost, and unit/kilogram/day cost will be analyzed using a paired t test. Differences in hospitalizations, emergency visits, and hypoglycemia occurrences will be analyzed using chi-square.
- | NovoLog (insulin aspart) / Novo Nordisk
Phase classification, Trial completion date, Trial termination, Trial primary completion date: IINDU: Insulin Infusion Diabetes Ulcer (clinicaltrials.gov) - Dec 23, 2020
P=N/A, N=40, Terminated, Sponsor: Karolinska Institutet
Differences in hospitalizations, emergency visits, and hypoglycemia occurrences will be analyzed using chi-square. Phase classification: P4 --> P=N/A | Trial completion date: Nov 2017 --> Dec 2020 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2020; participants are no longer being examined or receiving intervention
- || Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V). (Pubmed Central) - Dec 17, 2020
P4
Given the current lack of clinical data, this study will provide evidence supporting safe and effective glycemic control using basal insulin glargine-based therapy plus OADs compared with twice-daily premixed insulin in Chinese patients with T2DM after short-term IIT. This will assist physicians by providing a wider choice of treatments.
- | metformin / Generic mfg.
Trial completion, Enrollment change: DIARA2: Late Metabolic Effects of Metformin Therapy in Gestational Diabetes (clinicaltrials.gov) - Dec 11, 2020
P=N/A, N=173, Completed, Sponsor: Turku University Hospital
This will assist physicians by providing a wider choice of treatments. Enrolling by invitation --> Completed | N=317 --> 173
- || ultra-rapid-acting concentrated insulin aspart (AT278) / Arecor
New P1 trial: AT278 and NovoRapid (clinicaltrials.gov) - Dec 8, 2020
P1, N=38, Recruiting, Sponsor: Arecor Limited
- || pramlintide/insulin A21G (ADO09) / Adocia
Trial completion: A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 30, 2020
P1/2, N=44, Completed, Sponsor: Adocia
Enrolling by invitation --> Completed | N=317 --> 173 Recruiting --> Completed
- | Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 20, 2020
P4, N=226, Completed, Sponsor: Emory University
Recruiting --> Completed Active, not recruiting --> Completed
- | NovoLog (insulin aspart) / Novo Nordisk
@novonordiskus how can I place an order online for NovoFine® Plus The 32G, 4 mm pen needle (Twitter) - Nov 17, 2020
- || NovoLog (insulin aspart) / Novo Nordisk
PK/PD data, Journal: The Pharmacokinetics, Pharmacodynamics and Bioequivalence of Insulin Aspart Produced by the United Laboratories Evaluated by Euglycemic Clamp Study (Pubmed Central) - Nov 14, 2020
No hypoglycemic events, allergic reactions, or local injection adverse reaction occurred in this trial. The tested IAsp has comparable relative bioavailability to the reference NovoRapid .
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Dragi @novonordisk sta se desava sa vasim insulinom FIASP za trziste Srbije? Nakon mesec dana koriscenja FIASP vecina ima los HbA1C i vraca se na Novorapid. (Twitter) - Nov 10, 2020
- || IDegLira (insulin degludec/liraglutide) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal, HEOR: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. (Pubmed Central) - Nov 7, 2020
P3
Odds of achieving double or triple composite outcomes of HbA1c reduction without hypoglycemia and/or without weight gain were greatest for IDegLira. Short-term cost analyses based on the triple composite outcomes suggest that IDegLira is a cost-effective treatment option in the United States compared with either uptitration of IGlar U100 or basal-bolus therapy.
- || NovoLog (insulin aspart) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
@SenateVA @JerryMoran @jontester https://t.co/W62xps1lJ7 #Trulicity is made by EliLily @LillyPad #Novolog made by Novo Nordisk A/S (Twitter) - Nov 5, 2020
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (clinicaltrials.gov) - Nov 1, 2020
P3, N=353, Recruiting, Sponsor: Novo Nordisk A/S
Short-term cost analyses based on the triple composite outcomes suggest that IDegLira is a cost-effective treatment option in the United States compared with either uptitration of IGlar U100 or basal-bolus therapy. Not yet recruiting --> Recruiting
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report. (Pubmed Central) - Oct 26, 2020
Report of extreme dysregulation of chronic conditions such as diabetes in patients with COVID-19 may help clinicians to better take care of patients during the pandemic of SARS-CoV-2. To the best of our knowledge this is the first description of extremely high-dose insulin requirement in patient with COVID-19.
- | HinsBet (human insulin) / Adocia, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas (clinicaltrials.gov) - Oct 20, 2020
P2/3, N=45, Enrolling by invitation, Sponsor: Massachusetts General Hospital
To the best of our knowledge this is the first description of extremely high-dose insulin requirement in patient with COVID-19. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (clinicaltrials.gov) - Oct 19, 2020
P3, N=353, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || IDegLira (insulin degludec/liraglutide) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: IDegLira improves patient reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. (Pubmed Central) - Oct 11, 2020
P3
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 These findings combined with the DUAL VII results, suggest that IDegLira, through a more simplified regimen versus basal-bolus therapy, may help improve patient adherence and improve patient outcomes related to diabetes management, treatment burden, and mental health, which in turn may assist in the timely achievement of glycaemic control in clinical practice.
- | NovoLog (insulin aspart) / Novo Nordisk
Journal: Short-term fully closed-loop insulin delivery using faster insulin aspart compared to standard insulin aspart in type 2 diabetes. (Pubmed Central) - Oct 11, 2020
No episodes of severe hypoglycaemia or other serious adverse events occurred. In conclusion, short-term fully closed-loop in type 2 diabetes may require higher dose of faster insulin aspart compared to standard insulin aspart to achieve comparable glucose control.
- || Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Which brand of insulin? We know a couple pharmaceuticals were dropping price due to covid pandemic. Which ones? Lantus, Novolog? (Twitter) - Oct 9, 2020
- ||| Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Thank you for your advocacy Dr. Rajkumar. I’ve been a #type1diabetic for 35 years and have watched how a vial of fast acting insulin went from approximately $25 in 1996 to over $300 in 2020. The exact same insulin. #humalog #novolog It is outrageous. (Twitter) - Oct 7, 2020
- || Trial completion date, Trial primary completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Oct 7, 2020
P=N/A, N=150, Active, not recruiting, Sponsor: Weill Cornell Medical College in Qatar
In conclusion, short-term fully closed-loop in type 2 diabetes may require higher dose of faster insulin aspart compared to standard insulin aspart to achieve comparable glucose control. Trial completion date: Sep 2020 --> Oct 2021 | Trial primary completion date: Jun 2020 --> Dec 2020
- || NovoLog (insulin aspart) / Novo Nordisk
@teamnovonordisk hey! Wondering why my coupon for a month’s supply of Novolog for $25 is only getting me one pen. Any other discounts you can offer? @AmDiabetesAssn (Twitter) - Oct 5, 2020
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial. (Pubmed Central) - Oct 4, 2020
Fully closed-loop insulin delivery using either faster or standard insulin aspart was safe and efficient in achieving near-normal glucose concentrations outside postprandial periods. The closed-loop algorithm was better adjusted to the standard insulin aspart.